Every 10-Q that FibroGen, Inc (FGEN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FGEN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FGEN filings page.
Kyntra Bio, Inc. reported first-quarter 2026 revenue of $3.7 million, up from $2.7 million a year earlier, driven mainly by $3.5 million of drug product sales of roxadustat API and bulk product to Astellas. Operating costs and expenses were $17.6 million, roughly flat year over year.
The company posted a loss from continuing operations of $15.1 million, or $3.74 per share, compared with a loss of $16.8 million, or $4.15 per share, in 2025. Net loss was $15.2 million versus net income of $4.6 million last year, when results included $21.4 million of income from discontinued China operations. Cash, cash equivalents, short- and long-term investments, and accounts receivable totaled about $100.3 million, and management believes this will fund operations for at least 12 months. Kyntra continues to develop FG-3246 for metastatic castration-resistant prostate cancer and advance roxadustat into a planned Phase 3 trial for anemia in lower-risk MDS.
FibroGen, Inc. (FGEN) reported Q3 2025 results highlighted by the divestiture of its China operations to AstraZeneca for total consideration of $220.4 million. The company received $210.4 million at closing on August 29, 2025 and used approximately $80.9 million to repay its senior secured term loan facilities, interest, and related fees.
Results reflect discontinued operations for China: income from discontinued operations was $213.8 million in the quarter, including a $52.2 million gain on divestiture. From continuing operations, revenue was $1.1 million and loss was $13.1 million. Net income was $200.6 million, driven by the discontinued operations gain. Cash and cash equivalents were $118.0 million as of September 30, 2025, up from $50.5 million at year-end 2024.
The company effected a 1‑for‑25 reverse stock split on June 16, 2025. Shares outstanding were 4,045,445 as of October 31, 2025. Management now believes existing cash will fund planned operating requirements for at least 12 months following issuance. FibroGen initiated a Phase 2 study of FG‑3246 in mCRPC and aligned with the FDA on key elements of a planned Phase 3 for roxadustat in lower‑risk MDS.
FibroGen, Inc. reported condensed consolidated results for the quarter ended June 30, 2025. Total assets were $178.1 million versus $214.5 million at year-end 2024, and the company reported a consolidated total deficit of $202.5 million. For continuing operations, total revenue was $1.35 million for the quarter and $4.09 million for the six months ended June 30, 2025. The company recorded a net loss of $7.6 million for the quarter and $3.0 million for the six-month period; income from discontinued operations was $6.08 million for the quarter and $27.49 million for six months.
The company entered a share purchase agreement to sell FibroGen International to AstraZeneca for $85 million plus the net cash in China, with closing expected in the third quarter of 2025 subject to China SAMR approval. Management disclosed substantial doubt about the company’s ability to continue as a going concern without closing the sale or obtaining additional financing and must satisfy a U.S. cash covenant of $18.75 million. The company has a $75 million senior secured term loan (principal) that is presented as current with maturity in May 2026 and a liability related to the sale of future revenues of approximately $63.0 million.